Establishment and characterization of canine mammary tumoroids for translational research
Open Access
- 3 February 2023
- journal article
- research article
- Published by Springer Nature in BMC Biology
- Vol. 21 (1) , 1-19
Abstract
Background: Cancer heterogeneity is a main obstacle for the development of effective therapies, as its replication in in vitro preclinical models is challenging. Around 96% of developed drugs are estimated to fail from discovery to the clinical trial phase probably because of the unsuitability and unreliability of current preclinical models (Front Pharmacol 9:6, 2018; Nat Rev Cancer 8: 147–56, 2008) in replicating the overall biology of tumors, for instance the tumor microenvironment. Breast cancer is the most frequent cancer among women causing the greatest number of cancer-related deaths. Breast cancer can typically be modeled in vitro through the use of tumoroids; however, current approaches using mouse tumoroids fail to reproduce crucial aspect of human breast cancer, while access to human cells is limited and the focus of ethical concerns. New models of breast cancer, such as companion dogs, have emerged given the resemblance of developed spontaneous mammary tumors to human breast cancer in many clinical and molecular aspects; however, they have so far failed to replicate the tumor microenvironment. The present work aimed at developing a robust canine mammary tumor model in the form of tumoroids which recapitulate the tumor diversity and heterogeneity. Results: We conducted a complete characterization of canine mammary tumoroids through histologic, molecular, and proteomic analysis, demonstrating their strong similarity to the primary tumor. We demonstrated that these tumoroids can be used as a drug screening model. In fact, we showed that paclitaxel, a human chemotherapeutic, could kill canine tumoroids with the same efficacy as human tumoroids with 0.1 to 1 μM of drug needed to kill 50% of the cells. Due to easy tissue availability, canine tumoroids can be produced at larger scale and cryopreserved to constitute a biobank. We have demonstrated that cryopreserved tumoroids keep the same histologic and molecular features (ER, PR, and HER2 expression) as fresh tumoroids. Furthermore, two cryopreservation techniques were compared from a proteomic point of view which showed that tumoroids made from frozen material allowed to maintain the same molecular diversity as from freshly dissociated tumor. Conclusions: These findings revealed that canine mammary tumoroids can be easily generated and may provide an adequate and more reliable preclinical model to investigate tumorigenesis mechanisms and develop new treatments for both veterinary and human medicine.Keywords
Funding Information
- ITMO Cancer AVIESAN
- Inserm
This publication has 50 references indexed in Scilit:
- A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapiesCritical Reviews in Oncology/Hematology, 2013
- Classification and Grading of Canine Mammary TumorsVeterinary Pathology, 2011
- Andromeda: A Peptide Search Engine Integrated into the MaxQuant EnvironmentJournal of Proteome Research, 2011
- Guiding the Optimal Translation of New Cancer Treatments From Canine to Human Cancer PatientsClinical Cancer Research, 2009
- Universal sample preparation method for proteome analysisNature Methods, 2009
- Comparative expression pathway analysis of human and canine mammary tumorsBMC Genomics, 2009
- MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantificationNature Biotechnology, 2008
- Translation of new cancer treatments from pet dogs to humansNature Reviews Cancer, 2008
- Incidence of and survival after mammary tumors in a population of over 80,000 insured female dogs in Sweden from 1995 to 2002Preventive Veterinary Medicine, 2005
- Spontaneous tumors in dogs and cats: Models for the study of cancer biology and treatmentCancer and Metastasis Reviews, 1990